JMP Securities Reiterates Market Outperform on Integra Lifesciences, Maintains $55 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst David Turkaly has reiterated a 'Market Outperform' rating on Integra Lifesciences (NASDAQ:IART) and maintained a price target of $55. This reaffirmation of the company's stock performance and price target suggests confidence in Integra Lifesciences' future market performance.
December 14, 2023 | 5:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst David Turkaly has maintained a 'Market Outperform' rating and a price target of $55 for Integra Lifesciences (NASDAQ:IART), indicating a positive outlook on the stock.
The reiteration of a 'Market Outperform' rating and the maintenance of a $55 price target by a reputable analyst could lead to increased investor confidence in Integra Lifesciences, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100